When treating refractory kidney cancer, clinicians prioritize regimens offering the most durable initial response. They argue against “saving” effective drugs for later, as disease progression is traumatic for patients and many never successfully receive subsequent lines of therapy. The goal is long-term disease control now, not preserving theoretical future options.

A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.

The ELEGANT trial uses a "switch strategy," introducing elicestrin only after 2-5 years of standard therapy. This design pragmatically adapts to the evolving clinical landscape where CDK4/6 inhibitors are now standard initial treatment, ensuring the trial's relevance by testing the drug in a post-CDK4/6 inhibitor setting.

Three major trials (RIGHT Choice, PADMA, OMBRE) definitively show that starting with a CDK4/6 inhibitor plus endocrine therapy is superior to upfront chemotherapy for newly diagnosed, symptomatic metastatic breast cancer. This approach provides better progression-free survival without the toxicity of chemotherapy and, critically, does not result in a slower time to response.

New CDK inhibitors that also target CDK2 show great activity in models resistant to current CDK4/6 agents. Instead of being reserved for later use, they are already being tested in frontline trials. The strategy, similar to that of ALK inhibitors in lung cancer, is that using the best drug first may prevent or significantly delay the onset of resistance.

Patients are often unprepared that finishing active treatment or achieving "no evidence of disease" is not the end of their struggle. Survivorship introduces a distinct phase of challenges, including managing long-term side effects, PTSD, and fear of recurrence, which requires different support.

In high-risk, BRCA-positive patients eligible for both, clinicians favor giving a PARP inhibitor first. The rationale is based on established survival data, shorter one-year duration, and emerging biological evidence suggesting BRCA2-mutated tumors may be resistant to CDK4/6 inhibitors due to concurrent RB gene loss.

Large real-world databases show elacestrant monotherapy achieves a median time-to-next-treatment of over 8 months. This impressive outcome aligns with the most favorable subgroup from the pivotal EMERALD trial (patients on prior CDK4/6i >12 months), suggesting that clinicians are successfully identifying the ideal candidates for this therapy in routine practice.

A simple clinical biomarker—having received a prior CDK4/6 inhibitor for over 12 months—identifies patients likely to achieve significant progression-free survival (nearly nine months) with single-agent elacestrant. This allows clinicians to select patients for monotherapy without complex genomic profiling.